Small-cap pharma stock, involved in the engaged in manufacturing and export of active pharmaceutical ingredients, surged 8.5 percent following a 93.22 percent year-on-year growth in net profit for Q2 FY25.
Share price variations:
With a market capitalization of Rs. 4,767.00 crores, Supriya Lifescience Ltd. rose to an intraday high of Rs. 601.65 representing an 8.5 percent increase from its previous closing price of Rs. 554.35 per share.
Reason for the Rise:
According to exchange filings, Supriya Lifescience Ltd reported a 93.22 percent year-on-year increase in net profit for Q2 FY25, reaching Rs 46.14 crore, up from Rs 23.88 crore in Q2 FY24. On a quarter-on-quarter basis, net profit surged by 3.3 percent, rising from Rs. 44.64 crore in Q1 FY25.
Revenue grew by 18.27 percent year-on-year to Rs. 168.62 crore, compared to Rs. 142.56 crore in the same period last year. Sequentially, revenue increased by 3.5 percent from Rs. 162.85 crore in Q1 FY25.
The business mix revenue contribution is led by the Analgesic and Anesthetic segments at 54.9 percent, followed by Vitamins at 11.6 percent, Anti-histamines at 9.3 percent, Anti-Asthmatic at 9.2 percent, Anti-allergic at 5.2 percent, and Anti-hypertensive at 1.8 percent.
For the first half of FY25, revenue rose by 19.44 percent to Rs. 331.47 crores, up from Rs. 277.5 crores in H1 FY24, while net profit increased by 73.28 percent, reaching Rs. 90.79 crores compared to Rs. 52.39 crores in the previous year.
About the company:
Incorporated in 2008, Supriya Lifescience Ltd is engaged in the manufacturing and export of active pharmaceutical ingredients(APIs). As of October the company has a product basket of 32 APIs and is the largest exporter of chlorpheniramine maleate, ketamine hydrochloride, and salbutamol sulphate from India.
In FY24, exports contributed approximately 79% of the company’s revenue, with the top 10 clients accounting for 49% of total revenue. The company operates four manufacturing blocks over a 23,806 sq. mt area, with a reactor capacity of 597 KL per day.
Region-wise, revenue distribution for Q2FY25 is 45% from Europe, 32% from Asia, 14% from Latin America and the Caribbean, 4% from North America, and 5% from other regions, serving a customer base of over 1,700 across 86 countries.
Written By Joseph Pv
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
